Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 3/20 | 0.39 |
| ▸ | GGT1 | P19440 | 4/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662805 | 0.84 | GFPT1 (0.34) | GFPT1 | |
| SCHEMBL10187391 | 0.83 | GFPT1 (0.46) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL829989 | 0.82 | GFPT1 (0.47) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL542282 | 0.82 | GFPT1 (0.52) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL1973452 | 0.82 | GFPT1 (0.47) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL25345631 | 0.82 | GFPT1 (0.52) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL542281 | 0.82 | GFPT1 (0.52) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL29560900 | 0.82 | GFPT1 (0.47) | GFPT1SLC7A5GRIK1PTGS1SLC7A11 | |
| SCHEMBL12520125 | 0.79 | NOS2 (0.46) | GRIK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12648290 | 0.79 | GFPT1 (0.54) | GFPT1SLC7A5GRIK1CASRSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | AMBRX, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220411469-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220257720-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2022-08-18 | — | — | US | disclosed |
| WO-2015006555-A2 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140296487-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-8846876-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Abrx, Inc. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166559-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012024452-A2 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2009117622-A2 | MODIFIED FGF-23 POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008137471-A2 | MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | GFPT1 1477/4885SLC7A5 2199/4885GRIK1 4498/4885 |
| US-20220411469-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | GFPT1 253/4885SLC7A5 127/4885GRIK1 3946/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GFPT1 1322/4885SLC7A5 264/4885GRIK1 4775/4885 |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | FCGR2A, FCGR3B, FCGR1A | GFPT1 373/4885SLC7A5 888/4885GRIK1 2959/4885 |
| US-20140296487-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | GFPT1 2296/4885SLC7A5 3949/4885GRIK1 4278/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GFPT1 3816/4885SLC7A5 2905/4885GRIK1 771/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | GFPT1 634/4885SLC7A5 2188/4885GRIK1 1610/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GFPT1 1024/4885SLC7A5 221/4885GRIK1 4755/4885 |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | GFPT1 2940/4885SLC7A5 4040/4885GRIK1 2141/4885 |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | DNPEP, LNPEP, ANPEP | GFPT1 559/4885SLC7A5 310/4885GRIK1 1635/4885 |
| US-20220257720-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP3 | GFPT1 753/4885SLC7A5 2122/4885GRIK1 1657/4885 |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | CSF3R, GMFG, HDGF | GFPT1 634/4885SLC7A5 2188/4885GRIK1 1610/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | GFPT1 753/4885SLC7A5 2122/4885GRIK1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.